NON-SMALL CELL LUNG CANCER

This early-stage study tested a new drug called DCC-3116, alone or with other targeted therapies, in people with advanced solid tumors that have certain gene mutations (RAS/MAPK pathway). The trial was terminated early, so results are limited. It involved 91 participants and aime…

This early-phase study tested a new drug (PF-07265028) alone or with another drug (sasanlimab) in people with advanced solid tumors like lung, stomach, and head/neck cancers. The goal was to find the safest dose and see if the drug shrinks tumors. The study was stopped early, and…

This study tested a drug called tovorafenib in people aged 12 and older whose cancers had returned or worsened and had certain gene changes (MAPK pathway). The goal was to see if the drug could shrink tumors. The study was stopped early, so results are limited.

This early-phase study looked at the safety of giving radiation therapy either before or after an immunotherapy drug (pembrolizumab) in 13 people with advanced non-small cell lung cancer. The goal was to find the best order to reduce side effects and improve tumor shrinkage. The …

This study tested an experimental drug called telisotuzumab vedotin for people with a specific type of advanced lung cancer (non-squamous non-small cell) that has a MET gene amplification. The goal was to see if the drug could shrink tumors. The trial was stopped early after enro…

This study tested a new drug called OC-001, given alone or with an immunotherapy drug (Avelumab), in people with advanced cancers that had spread. The goal was to check safety and how the drug moves through the body. The study was stopped early and involved 73 participants with v…

This study tested whether the drug olaparib could help control advanced non-small cell lung cancer (NSCLC) after initial chemotherapy. Only patients whose cancer responded to platinum-based chemotherapy were eligible. The trial was terminated early, and results are not yet fully …

This study tested a personalized treatment where a patient's own immune cells were modified in a lab to recognize and attack unique markers on their cancer cells. It involved 8 people with advanced solid tumors like lung, pancreatic, or ovarian cancer that had stopped responding …

This study tested a new drug (SOT101) combined with pembrolizumab in 166 people with advanced solid tumors like lung, colon, and ovarian cancer. The goal was to see if the combination could shrink tumors. The study was stopped early, and participants were expected to need ongoing…

This early-phase study tested a new medicine called PF-07921585, given alone or with another drug (sasanlimab), in adults with advanced solid tumors like lung, bladder, kidney, skin, head and neck, or colorectal cancer. The goal was to check safety and how the body handles the dr…

This study tested a new drug called SAR444245 combined with other cancer treatments for people with advanced non-small cell lung cancer or pleural mesothelioma. The goal was to see if the combination could shrink tumors. The trial was stopped early, so results are limited. About …

This early-stage study tested an experimental drug called TAS3351 in 18 people with advanced non-small cell lung cancer that had a specific genetic change (EGFR C797S mutation). The goal was to see if the drug was safe and could shrink tumors. The study was stopped early, so resu…

This early-stage study tested a new drug called BDC-3042, alone or with another drug (cemiplimab), in 17 people with advanced cancers such as breast, kidney, ovarian, head and neck, colorectal, lung, and skin cancer. The main goal was to check safety and find the right dose. The …

This early-phase study tested a new immunotherapy called IMU-201 in 24 adults with advanced non-small cell lung cancer. The treatment aimed to help the immune system fight cancer, given alone or with other drugs. The trial was terminated early, so results are limited.

This study tested an experimental drug called vobramitamab duocarmazine in people with advanced prostate cancer and other solid tumors that had stopped responding to standard treatments. The goal was to see if the drug could shrink tumors or delay cancer growth. The trial was ter…

This study tested a new drug called PRO1107 in 33 people with advanced solid tumors, including ovarian, endometrial, and lung cancers. The goal was to check safety and see if the drug could shrink tumors. The trial was stopped early, so results are limited.

This study tested giving immunotherapy drugs (durvalumab with or without tremelimumab) along with standard radiation before surgery for stage III non-small cell lung cancer. The goal was to see if this approach is safe and does not delay planned surgery. Only 9 people took part b…

This study tested two immunotherapy drugs, ipilimumab and nivolumab, as a first treatment for people with advanced non-small cell lung cancer that had spread. The goal was to see how well the drugs shrank tumors and to study biomarkers. Only 5 people enrolled before the study was…

This early-stage study tested a new drug called MGY825 in 41 adults with advanced non-small cell lung cancer that had certain genetic changes. The main goal was to check the drug's safety and find the right dose. The study was stopped early, so results are limited.

This early-phase study tested a new medicine, PF-08046032, alone or with another drug (sasanlimab) in 6 adults with advanced lymphomas or solid tumors that had spread or stopped responding to standard treatments. The main goals were to check safety and find the right dose. The st…

This study aimed to see if the drug capmatinib, given before and after surgery, could improve outcomes for people with early-stage non-small cell lung cancer that has a specific genetic change (MET mutation). Only 4 people enrolled, and the trial was stopped early, so we don't ha…

This study tested whether adding the immunotherapy drug pembrolizumab (Keytruda) to precise radiation therapy (SBRT) could help people with early-stage non-small cell lung cancer who couldn't have surgery. The trial was stopped early, so results are limited. It involved 448 adult…

This study tested a combination of two immunotherapy drugs (tiragolumab and atezolizumab) in people with a type of lung cancer that had spread to the brain but wasn't causing symptoms. The goal was to see if the treatment could control the brain tumors and delay the need for radi…

This study tested a new combination of two drugs (ociperlimab and tislelizumab) against the standard drug pembrolizumab for people with advanced non-small cell lung cancer whose tumors have high PD-L1 levels. The trial was stopped early, but researchers measured how long patients…

This early-stage study tested a new cell therapy called ITIL-306 for people with advanced solid tumors (ovarian, lung, or kidney cancer) that had stopped responding to standard treatments. The therapy used a patient's own immune cells, modified to better attack tumors. The trial …

This early-stage trial tested a new drug called DCC-3084, alone or with other cancer treatments, in 29 people with advanced solid tumors that have specific genetic changes (MAPK pathway). The study was stopped early, so results are limited. The goal was to find safe doses and see…

This study looked at whether two immunotherapy drugs, nivolumab and ipilimumab, could control advanced non-small cell lung cancer without chemotherapy. It enrolled 5 adults whose cancer had spread and whose tumors had low PDL1 levels. The main goal was to see how long the disease…

This study tested a new drug (HBI-8000) combined with an existing immunotherapy (pembrolizumab) for people with advanced non-small cell lung cancer. The goal was to see if the combination was safe and effective. Only 5 people took part before the study was stopped early.

This study tested a new drug, nogapendekin alfa inbakicept, combined with standard treatments for people with advanced or metastatic non-small cell lung cancer. The trial aimed to see if the combination could slow cancer growth and improve survival. However, the study was termina…

This early-stage trial tested a new drug called MRTX0902, alone or with another drug (adagrasib), in 64 people with advanced solid tumors (like lung or colon cancer) that have specific KRAS gene mutations. The main goals were to check safety and find the right dose. The study was…

This study tested whether adding an extra drug (canakinumab) to standard immunotherapy plus chemotherapy could help people with advanced non-small cell lung cancer live longer or slow their cancer. The trial included 673 adults who had not received prior treatment. Unfortunately,…

This early-stage study tested a new drug called AUR106 in 21 adults with advanced solid tumors like lung, stomach, bladder, kidney, colon, or esophageal cancer that had come back or spread. The main goal was to find the safest dose and understand how the drug works in the body. T…

This study tested whether injecting a drug called vidutolimod directly into tumors, combined with an intravenous immunotherapy (cemiplimab), could shrink or control advanced cancers like Merkel cell carcinoma, skin cancer, breast cancer, and lung cancer. The trial enrolled 77 adu…

This early-stage study tested a new drug called TAS2940 in 29 people with advanced solid tumors (like lung, breast, or brain cancer) that had certain genetic changes (EGFR or HER2). The goal was to find a safe dose and see if it could shrink tumors. The trial was stopped early, s…

This early-stage study tested a new drug called PF-07826390, given alone or with another drug (sasanlimab), in people with advanced solid tumors like lung, colon, kidney, and ovarian cancers. The goal was to check safety, find the right dose, and see if the drug shrinks tumors. O…

This early-phase study tested a combination of an immunotherapy drug (atezolizumab) and a gene therapy (IL-12) in 13 people with advanced non-small cell lung cancer that had worsened after initial immunotherapy. The goal was to see if the combination was safe and could help contr…

This early-stage trial tested a new drug called MYTX-011 for people with advanced non-small cell lung cancer (NSCLC) that had spread or come back after standard treatments. The drug is an antibody-drug conjugate designed to deliver a potent chemotherapy directly to cancer cells. …

This study tested a new treatment for advanced non-small cell lung cancer using a patient's own immune cells (TILs) combined with an immunotherapy drug. The goal was to see if the combination was safe and tolerable. However, the trial was terminated early and only enrolled 2 peop…

This early-phase study tested a new drug, BT-001, injected directly into tumors of people with advanced solid cancers (like melanoma or lung cancer). Some participants also received the immunotherapy pembrolizumab. The goal was to check safety and find the right dose. The study w…

This study tested whether giving a higher dose of radiation to the main tumor could be safe for people with non-small cell lung cancer. It included 6 adults with stage II or III lung cancer who could not have surgery. The trial was ended early, so results are limited.

This early-stage study tested a new drug called SO-C101, either alone or with another drug (pembrolizumab), in 115 people with advanced solid tumors like lung, kidney, or skin cancer. The main goal was to check safety and find the right dose. The study was stopped early, so resul…

This early-stage study tested a new experimental drug (PF-07820435) alone or with another drug (sasanlimab) in people with advanced solid tumors like lung, skin, and kidney cancers. The goal was to check safety and find the right dose. Only 9 people took part before the study was…

This study tested a combination of two drugs, tarloxotinib and sotorasib, in people with advanced non-small cell lung cancer that has a specific genetic change called KRAS G12C. Participants had already tried other treatments, including a KRAS-targeting drug, but their cancer con…

This study aimed to see if adding a type of immunotherapy (durvalumab) to two different schedules of precise radiation therapy could improve quality of life for people with advanced non-small cell lung cancer. Only one person was enrolled before the study was stopped early. The m…

This study looked at whether a mix of exercises could reduce fatigue and improve fitness and quality of life in people with advanced lung cancer. It was designed for patients on long-term immunotherapy. However, the study was stopped early and only enrolled 2 people, so no clear …

This study looked at whether monitoring daily step counts in people with locally advanced non-small cell lung cancer during chemoradiotherapy could help doctors provide better supportive care and reduce hospital visits or treatment delays. Only 3 participants were enrolled before…

This study tested a mobile app called ApricityCare to help ethnic and racial minority patients with non-small cell lung cancer report side effects from immunotherapy. The goal was to reduce treatment delays and hospital visits. The study was terminated early, so results are limit…

This study looked at how long immunotherapy (a treatment that helps the immune system fight cancer) should be given to people with non-small cell lung cancer who had already responded well to it. The goal was to see if stopping treatment earlier or continuing longer was better. O…

This early-phase trial tested whether combining high-dose vitamin C with the immunotherapy drug durvalumab could boost the immune system's attack on non-small cell lung cancer before surgery. Only one person took part before the study was stopped. The main goal was to measure imm…